Resistance testing should guide initial treatment choice in HIV
A substantial portion of antiretroviral-naïve patients are infected with transmitted drug-resistant HIV with one or more drug-resistant mutations, and they are much more likely to experience treatment failure, according to research published in The Lancet Infectious Diseases.
A substantial portion of antiretroviral-naïve patients are infected with transmitted drug-resistant HIV with one or more drug-resistant mutations, and they are much more likely to experience treatment failure, according to research published in The Lancet Infectious Diseases.
Linda Wittkop, MD, of the University Bordeaux, Segalen, France, and colleagues participating in European multicohort study, studied 10,056 patients who were receiving combination antiretroviral therapy (cART) and who had undergone genotypic testing for drug-resistant mutation. The goal was to determine the effect of transmitted drug resistance (TDR) on cART.
Of the 10,056 patients, 475 (4.7%) had at least 1 mutation, but received fully-active cART; 479 (4.8%) had at least 1 mutation and resistance to at least 1 drug. The other 9,102 patients had HIV without TDR. Estimates of virological failure at 12 months were 4.2% for patients in the no-TDR group; 4.7% for those in the TDR and fully-active cART group; and 15.1% for those in the TDR and resistant group.
"These findings confirm present treatment guidelines for HIV, which state that the initial treatment choice should be based on resistance testing in treatment-naïve patients," the authors concluded.
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
ICER Finds Insurers Struggled to Provide Fair Access for Obesity Drugs
December 19th 2024The Institute for Clinical and Economic Review assessed the formularies of 11 payers, covering 57 million people, to determine access for drugs that the organization had reviewed in 2022 for cost-effectiveness.
Read More
